Nothing Special   »   [go: up one dir, main page]

MX2022012386A - Compuestos inhibidores de metaloenzimas. - Google Patents

Compuestos inhibidores de metaloenzimas.

Info

Publication number
MX2022012386A
MX2022012386A MX2022012386A MX2022012386A MX2022012386A MX 2022012386 A MX2022012386 A MX 2022012386A MX 2022012386 A MX2022012386 A MX 2022012386A MX 2022012386 A MX2022012386 A MX 2022012386A MX 2022012386 A MX2022012386 A MX 2022012386A
Authority
MX
Mexico
Prior art keywords
inhibitor compounds
metalloenzyme inhibitor
metalloenzyme
compounds
metalloenzymes
Prior art date
Application number
MX2022012386A
Other languages
English (en)
Inventor
Steven Sparks
Christopher M Yates
Sammy R Shaver
William J Hoekstra
Original Assignee
Selenity Therapeutics Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selenity Therapeutics Bermuda Ltd filed Critical Selenity Therapeutics Bermuda Ltd
Publication of MX2022012386A publication Critical patent/MX2022012386A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen compuestos que tienen actividad moduladora de metaloenzimas y métodos de tratamiento de enfermedades, trastornos o síntomas de los mismos mediados por tales metaloenzimas.
MX2022012386A 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas. MX2022012386A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29

Publications (1)

Publication Number Publication Date
MX2022012386A true MX2022012386A (es) 2022-11-30

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007892A MX2019007892A (es) 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas.
MX2022012386A MX2022012386A (es) 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019007892A MX2019007892A (es) 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas.

Country Status (15)

Country Link
US (3) US10085984B2 (es)
EP (2) EP3562487B1 (es)
JP (2) JP7227157B2 (es)
KR (1) KR102690885B1 (es)
CN (1) CN110691598A (es)
AU (2) AU2017387033B2 (es)
BR (1) BR112019013478A2 (es)
CA (1) CA3055292A1 (es)
DK (1) DK3562487T3 (es)
ES (1) ES2967119T3 (es)
FI (1) FI3562487T3 (es)
MX (2) MX2019007892A (es)
RU (1) RU2764666C2 (es)
TW (1) TWI786078B (es)
WO (1) WO2018125800A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6189865B2 (ja) 2012-01-20 2017-08-30 ヴィアメット ファーマスーティカルズ,インコーポレイテッド 金属酵素阻害薬化合物
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
AU2020207051A1 (en) * 2019-01-08 2021-08-05 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
EP4153566A1 (en) 2020-05-19 2023-03-29 Bayer CropScience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
KR20230024343A (ko) 2020-06-10 2023-02-20 바이엘 악티엔게젤샤프트 살진균제로서의 아자비시클릴-치환된 헤테로사이클

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DE69009946T2 (de) 1989-12-04 1994-11-03 Searle & Co System zur transdermalen Albuterol Applikation.
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ マイニング アンド マニュファクチャリング カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2465247C (en) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
DE60305446T4 (de) * 2002-01-07 2009-07-09 Eisai R&D Management Co., Ltd. Desazapurine und deren verwendung
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CA2596013C (en) 2005-01-28 2012-06-05 Daewoong Pharmaceutical Co., Ltd. Benzoimidazole derivatives and pharmaceutical composition comprising the same
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
AR068072A1 (es) 2007-04-19 2009-11-04 Novartis Ag Derivados de bencimidazoles, composiciones farmaceuticas y usos
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
MX2009013753A (es) 2007-06-26 2010-01-26 Sanofi Aventis Una sintesis regioselectiva catalizada por cobre de bencimidazoles y azabencimidazoles.
CA2701115A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
EP2254572B1 (en) 2008-02-07 2013-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
EP2429995B1 (en) 2009-05-15 2014-01-22 Novartis AG Aryl pyridine as aldosterone synthase inhibitors
EP2501678B1 (en) 2009-11-17 2015-09-23 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
WO2012012478A1 (en) * 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
CA2812855C (en) 2010-10-08 2017-12-19 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2013033901A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
WO2014179303A1 (en) 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP3558984B1 (en) * 2016-12-20 2023-08-02 FMC Corporation Fungicidal oxadiazoles
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
RU2764666C2 (ru) 2022-01-19
WO2018125800A2 (en) 2018-07-05
CN110691598A (zh) 2020-01-14
RU2019123854A3 (es) 2021-05-12
JP7227157B2 (ja) 2023-02-21
KR102690885B1 (ko) 2024-08-02
US10085984B2 (en) 2018-10-02
CA3055292A1 (en) 2018-07-05
WO2018125800A3 (en) 2018-08-16
AU2017387033A1 (en) 2019-08-15
US20210322409A1 (en) 2021-10-21
RU2019123854A (ru) 2021-02-01
KR20190129034A (ko) 2019-11-19
EP3562487B1 (en) 2023-11-29
ES2967119T3 (es) 2024-04-26
BR112019013478A2 (pt) 2020-01-07
TWI786078B (zh) 2022-12-11
EP4311577A3 (en) 2024-04-17
EP4311577A2 (en) 2024-01-31
US11040034B2 (en) 2021-06-22
MX2019007892A (es) 2020-02-05
DK3562487T3 (da) 2024-01-02
EP3562487A4 (en) 2020-08-26
AU2024202860A1 (en) 2024-05-23
US20180185362A1 (en) 2018-07-05
JP2020510693A (ja) 2020-04-09
AU2017387033B2 (en) 2024-02-01
EP3562487A2 (en) 2019-11-06
JP2023071692A (ja) 2023-05-23
FI3562487T3 (fi) 2023-12-14
TW201831465A (zh) 2018-09-01
US20190008861A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX351943B (es) Compuestos inhibidores de metaloenzima.
MX2018016046A (es) Quinazolina y compuestos indol para tratar trastornos medicos.
IN2014DN00286A (es)
IN2014MN00093A (es)
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
IN2014DN06792A (es)
BR112017006664A2 (pt) terapias de combinação
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
MX2017015225A (es) Inhibidores de la autotaxina y sus usos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
WO2012058529A3 (en) Metalloenzyme inhibitor compounds